We have located links that may give you full text access.
Sex influence on outcomes of patients with systemic sclerosis-associated interstitial lung disease: an EUSTAR database analysis.
Rheumatology 2022 November 23
OBJECTIVE: Interstitial lung disease (ILD) is the leading cause of morbidity/mortality in systemic sclerosis (SSc). We aimed to study investigate the impact of sex on SSc-ILD.
METHODS: EUSTAR SSc patients with radiological-confirmed ILD and available %predicted forced vital capacity(%pFVC) were included. Demographics and disease features were recorded. Change in %pFVC over 12±6 months (cohort 1) was classified into stable (≤4%), mild (5-9%) and large progression (≥10%). In those with 2-year longitudinal %pFVC (cohort 2), %pFVC change at each 12±6 months interval was calculated. Logistic regression analyses (OR and 95%CI) and Cox proportional hazards models adjusted for age and %pFVC were applied.
RESULTS: 1136 male and 5253 female SSc-ILD patients were identified. Males were significantly younger, had a shorter disease duration, higher prevalence of CRP elevation, were had frequently a diffuse cutaneous involvement. In cohort 1(1655 females and 390 males), a higher percentage of males had stable ILD (74.4% versus 69.4%, p = 0.056). In multivariable analysis, disease duration and %pFVC(OR 0.99,0.98-0.99; 0.97,0.95-0.99) in males and age, %pFVC and anti-centromere(OR 1.02,1.00-1.04; 0.97,0.96-0.98; 0.39,0.245-0.63) in females were associated with large progression. The 1-year mortality rate was higher in males (5.1% versus 2.5%, p = 0.013). In cohort 2(849 females and 209 males), a higher percentage of females showed periods of large progression (11.7% versus 7.7%, p = 0.023), the percentage of patients with 0, 1 or 2 periods of worsening was not different. The overall death rate was 30.9% for males and 20.4% in females (p < 0.001). At survival analysis, male sex was a predictor of mortality (OR 1.95, 1.66-2.28).
CONCLUSIONS: Male SSc-ILD patients have a poorer prognosis and sex-specific predictors exist in SSc-ILD.
METHODS: EUSTAR SSc patients with radiological-confirmed ILD and available %predicted forced vital capacity(%pFVC) were included. Demographics and disease features were recorded. Change in %pFVC over 12±6 months (cohort 1) was classified into stable (≤4%), mild (5-9%) and large progression (≥10%). In those with 2-year longitudinal %pFVC (cohort 2), %pFVC change at each 12±6 months interval was calculated. Logistic regression analyses (OR and 95%CI) and Cox proportional hazards models adjusted for age and %pFVC were applied.
RESULTS: 1136 male and 5253 female SSc-ILD patients were identified. Males were significantly younger, had a shorter disease duration, higher prevalence of CRP elevation, were had frequently a diffuse cutaneous involvement. In cohort 1(1655 females and 390 males), a higher percentage of males had stable ILD (74.4% versus 69.4%, p = 0.056). In multivariable analysis, disease duration and %pFVC(OR 0.99,0.98-0.99; 0.97,0.95-0.99) in males and age, %pFVC and anti-centromere(OR 1.02,1.00-1.04; 0.97,0.96-0.98; 0.39,0.245-0.63) in females were associated with large progression. The 1-year mortality rate was higher in males (5.1% versus 2.5%, p = 0.013). In cohort 2(849 females and 209 males), a higher percentage of females showed periods of large progression (11.7% versus 7.7%, p = 0.023), the percentage of patients with 0, 1 or 2 periods of worsening was not different. The overall death rate was 30.9% for males and 20.4% in females (p < 0.001). At survival analysis, male sex was a predictor of mortality (OR 1.95, 1.66-2.28).
CONCLUSIONS: Male SSc-ILD patients have a poorer prognosis and sex-specific predictors exist in SSc-ILD.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app